InVivo Therapeutics is a research and clinical-stage biomaterials and biotechnology company focused on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. The Company is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for acute SCI, and Therapeutic Trails injection program for the treatment of chronic SCI.

Type
Public
HQ
Cambridge, US
Founded
2005
Size (employees)
37 (est)
InVivo Therapeutics was founded in 2005 and is headquartered in Cambridge, US
Report incorrect company information

Key People/Management at InVivo Therapeutics

Christopher McNulty

Christopher McNulty

CFO
Kenneth DiPietro

Kenneth DiPietro

Board Director
Pamela Stahl

Pamela Stahl

Chief Commercial Officer
Tamara Joseph

Tamara Joseph

Senior Vice President, General Counsel/Chief Compliance Officer
William DAgostino

William DAgostino

Senior Vice President, Operations
Ann Merrifield

Ann Merrifield

Chair of the Board
Show more

InVivo Therapeutics Office Locations

InVivo Therapeutics has an office in Cambridge
Cambridge, US (HQ)
One Kendall Square, Building 1400 East, Floor 4
Show all (1)
Report incorrect company information

InVivo Therapeutics Financials and Metrics

InVivo Therapeutics Revenue

USD

Net income (Q1, 2018)

(4.8 m)

EBIT (Q1, 2018)

(4.8 m)

Market capitalization (18-Jul-2018)

6.1 m

Closing share price (18-Jul-2018)

2

Cash (31-Mar-2018)

11.6 m
InVivo Therapeutics's current market capitalization is $6.1 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

General and administrative expense

7.6 m12.3 m11.5 m13.5 m

R&D expense

10.3 m10.1 m12.6 m11.1 m

Operating expense total

17.8 m22.4 m24.1 m24.6 m

EBIT

(17.8 m)(22.4 m)(24.1 m)(24.6 m)
Quarterly
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

13.5 m20.2 m21.5 m12.9 m

Prepaid Expenses

1.1 m184 k451 k

Current Assets

15 m20.7 m33.9 m13.8 m

PP&E

1.6 m938 k510 k
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

9.8 m20.9 m17.6 m24.5 m25.1 m22.1 m45.8 m41.6 m37.7 m14.4 m14.3 m16.4 m11.6 m

Prepaid Expenses

445 k378 k342 k543 k397 k268 k617 k682 k413 k940 k657 k475 k

Current Assets

10.7 m21.6 m18.3 m25.4 m25.9 m22.8 m46.7 m42.7 m38.4 m27.4 m22.9 m18 m13.1 m

PP&E

2.2 m2 m1.8 m1.4 m1.3 m1.1 m846 k736 k630 k395 k305 k190 k
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(18.3 m)(33.3 m)(23.4 m)(26.7 m)

Depreciation and Amortization

752 k689 k553 k395 k

Accounts Payable

(330 k)(48 k)489 k(23 k)

Cash From Operating Activities

(15.3 m)(16.3 m)(16.7 m)(19.7 m)
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Net Income

(5.1 m)(8.7 m)(10 m)(15.8 m)(26.3 m)(28.6 m)(6.6 m)(11.8 m)(18 m)(6.4 m)(12.7 m)(22.1 m)(4.8 m)

Depreciation and Amortization

195 k378 k568 k178 k352 k527 k146 k284 k417 k135 k264 k387 k40 k

Accounts Payable

(195 k)(307 k)(188 k)224 k384 k228 k(83 k)38 k35 k27 k(133 k)259 k240 k

Cash From Operating Activities

(4.2 m)(7.8 m)(11.1 m)(2.9 m)(7.1 m)(11 m)(4.2 m)(8.3 m)(12.3 m)(6.1 m)(11 m)(15.6 m)(3.7 m)
USDY, 2018

Financial Leverage

1.6 x
Show all financial metrics

InVivo Therapeutics Operating Metrics

FY, 2016

Facilities

1

Patents (US)

8

Patents (foreign)

8

Patents Pending

12
Show all operating metrics
Report incorrect company information

InVivo Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

InVivo Therapeutics Company Life and Culture

Report incorrect company information